Lv25
118 积分 2026-01-19 加入
Ivarmacitinib, a selective Janus kinase 1 inhibitor, in patients with moderate-to-severe active rheumatoid arthritis and inadequate response to conventional synthetic DMARDs: results from a phase III randomised clinical trial
12小时前
待确认
Tofacitinib and risk of cardiovascular outcomes: results from the Safety of TofAcitinib in Routine care patients with Rheumatoid Arthritis (STAR-RA) study
13小时前
已完结
Upadacitinib Versus Placebo or Adalimumab in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase III, Double‐Blind, Randomized Controlled Trial
2天前
已完结
Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach
7天前
已完结
Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis
8天前
已完结
2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis
8天前
已完结
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update
8天前
已完结
Efficacy and safety of JAK inhibitors in rheumatoid arthritis: update for the practising clinician
29天前
已完结
Targeting Janus Kinase (JAK) for Fighting Diseases: The Research ofJAK Inhibitor Drugs
1个月前
已完结
JAK inhibitor selectivity: new opportunities, better drugs?
1个月前
已完结
皖公网安备34019202002308
